The yin yang of sunitinib: One drug, two doses, and multiple outcomes

The yin yang of sunitinib: One drug, two doses, and multiple outcomes

Our recent work showed that sunitinib exerts dual effect on cancer cells in different dose ranges. In clinically relevant doses, cancer cells tolerate sunitinb cytotoxicity by upregulating pro-survival MCL-1 and activating mTORC1 signaling. Inhibition of MCL-1 or mTORC1 sensitized cancer cells to su...

Full description

Bibliographic Details
Main Author: Mohamed Elgendy
Format: Article
Language:English
Published: Taylor & Francis Group 2017-03-01
Series:Molecular & Cellular Oncology
Subjects:
autophagy
cell death
mcl-1
mtor
mtorc1
sunitinib
Online Access:http://dx.doi.org/10.1080/23723556.2017.1285385

Similar Items

Similar Items